Sarepta Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Sarepta Therapeutics Inc SRPT.OQ reported quarterly adjusted earnings of $1.89​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 7 cents. The mean expectation of twenty four analysts for the quarter was for earnings of 75 cents per share. Wall Street expected results to range from -6 cents to $1.00 per share.

• Revenue rose 68.4% to $611.09 million from a year ago; analysts expected $529.98 million.

• Sarepta Therapeutics Inc's reported EPS for the quarter was $1.89​.

• The company reported quarterly net income of $196.89 million.

• Sarepta Therapeutics Inc shares had fallen by 2.0% this quarter and lost 86.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14.9% in the last three months.​

• In the last 30 days, nine analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy," 18 "hold" and 5 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Sarepta Therapeutics Inc is $18.50, about 9.5% above its last closing price of $16.75

This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)